Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 3/20 | 0.33 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | CTSB | P07858 | 2/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.32 |
| ▸ | CTSH | P09668 | 1/20 | 0.32 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | LAP3 | P28838 | 3/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711078 | 1.00 | CAPN1 (0.33) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL1711940 | 0.91 | CAPN1 (0.34) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL1711374 | 0.91 | CAPN1 (0.34) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL1711607 | 0.83 | MMP8 (0.38) | CTSLCYP2C19 | |
| SCHEMBL1711440 | 0.83 | MMP8 (0.38) | CTSLCYP2C19 | |
| SCHEMBL6047668 | 0.83 | SLC7A5 (0.32) | — | |
| SCHEMBL1711578 | 0.80 | SLC7A5 (0.39) | — | |
| SCHEMBL2115692 | 0.77 | ARG1 (0.32) | — | |
| SCHEMBL3818712 | 0.77 | ARG1 (0.32) | — | |
| SCHEMBL2107432 | 0.76 | FOLH1 (0.46) | FOLH1NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11419944-B2 | Non-linear self-immolative linkers and conjugates thereof | BYONDIS B.V. (NL) | 2022-08-23 | — | — | US | disclosed |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BYONDIS B.V. (NL) | 2020-09-24 | — | — | US | disclosed |
| EP-3525826-B1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BYONDIS BV (NL) | 2020-07-22 | — | — | EP | disclosed |
| EP-3108886-B1 | CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | SYNTARGA BV (NL) | 2020-06-17 | — | — | EP | disclosed |
| EP-3525826-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | Synthon Biopharmaceuticals B.V. (NL) | 2019-08-21 | — | — | EP | disclosed |
| EP-1909846-B1 | TRIAZOLE-CONTAINING RELEASABLE LINKERS, CONJUGATES COMPRISING THE SAME AND PROCESSES FOR THEIR PREPARATION | SYNTARGA BV (NL) | 2018-12-26 | — | — | EP | disclosed |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-17 | — | — | US | disclosed |
| WO-2018069375-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2018-04-19 | — | — | WO | disclosed |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | BYONDIS B.V. (NL) | 2013-08-29 | — | — | US | disclosed |
| EP-2173739-B1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA BV (NL) | 2013-07-31 | — | — | EP | disclosed |
| EP-2560645-A2 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | Syntarga B.V. (NL) | 2013-02-27 | — | — | EP | disclosed |
| US-8158590-B2 | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation | SYNTARGA B.V. (NL) | 2012-04-17 | — | — | US | disclosed |
| WO-2011133039-A2 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | SYNTARGA B.V. (NL) | 2011-10-27 | — | — | WO | disclosed |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | BYONDIS B.V. (NL) | 2011-08-25 | — | — | US | disclosed |
| US-20110065767-A1 | Substituted CC-1065 Analogs and Their Conjugates | SYNTARGA B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
| EP-1909846-A2 | TRIAZOLE-CONTAINING RELEASABLE LINKERS, CONJUGATES THEREOF, AND METHODS OF PREPARATION | Syntarga B.V. (NL) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007018431-A2 | TRIAZOLE-CONTAINING RELEASABLE LINKERS AND CONJUGATES COMPRISING THE SAME | SYNTARGA B.V. (NL) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | DLST, ADSL, LANCL1 | CAPN1 3750/4885CTSK 1452/4885CTSL 700/4885 |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | PAICS, CD44, TRIM33 | CAPN1 3564/4885CTSK 183/4885CTSL 198/4885 |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | PCNA, CDC5L, TOP1 | CAPN1 935/4885CTSK 2716/4885CTSL 2010/4885 |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | CAPN1 872/4885CTSK 2646/4885CTSL 2112/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | CAPN1 966/4885CTSK 2616/4885CTSL 2271/4885 |
| US-20110065767-A1 | Substituted CC-1065 Analogs and Their Conjugates | PCNA, TOP1, TOP2B | CAPN1 904/4885CTSK 2675/4885CTSL 2058/4885 |
| US-11419944-B2 | Non-linear self-immolative linkers and conjugates thereof | DLST, ADSL, LANCL1 | CAPN1 3750/4885CTSK 1452/4885CTSL 700/4885 |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | CAPN1 872/4885CTSK 2646/4885CTSL 2112/4885 |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | PCNA, DCLRE1A, CDC5L | CAPN1 872/4885CTSK 2646/4885CTSL 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.